Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis – results of a 1 year longitudinal arthroscopic study in 422 patients  by Ayral, X. et al.
Synovitis: a potential predictive factor of structural progression
of medial tibiofemoral knee osteoarthritis e results of a 1 year
longitudinal arthroscopic study in 422 patients
X. Ayral M.D., Assistant Professor of Rheumatologyy*, E. H. Pickering Ph.D.z,
T. G. Woodworth M.D.z, N. Mackillop M.D.z and M. Dougados M.D., Professor of Rheumatologyy
yService de Rhumatologie B, Hoˆpital Cochin, AP-HP, Universite´ Rene´ Descartes, Paris, France
zPfizer, Groton, USA
Summary
Objective: To evaluate the prevalence of synovitis in painful medial tibiofemoral knee osteoarthritis (OA) and to evaluate correlation between
synovitis and the structural severity and progression of tibiofemoral cartilage damage.
Design: Study : multicenter, longitudinal, 1-year duration. Patients: primary painful knee OA (ACR criteria) of the medial tibiofemoral
compartment, with pain of the signal knee on at least 30 days in the past 2 months, medial joint space width R 2 mm, at least 10% of one
cartilage surface of the medial compartment affected by superﬁcial ﬁbrillation or worse at baseline arthroscopy. Arthroscopic parameters: knee
arthroscopy under local anesthesia was performed and videorecorded at entry and after 1 year. Medial chondropathy was scored by using
Socie´te´ Franc¸aise d’Arthroscopie (SFA) score (0e100) and reader’s overall assessment (VAS score, 100 mm). Progression of medial
chondropathy was deﬁned by a change in SFA and VAS scores over 4.5 and 8.0 mm after 1 year, respectively. Medial perimeniscal synovium
was scored as normal (few translucent and slender villi, ﬁne vascular network), reactive (proliferation of opaque villi), or inﬂammatory
(hypervascularization and/or proliferation of hypertrophic and hyperemic villi). Medial chondropathy and synovitis were scored by a single
reader blind to chronology of paired videotapes.
Results: Four hundred and twenty-two patients were enrolled (mean age: 61 years, females: 59%, body mass index: 31, mean disease
duration: 4 years) and completed the 1-year study. Synovial abnormalities were present in 50% of the patients with reactive and inﬂammatory
aspects in 29% and 21% of the patients, respectively. Patients with a reactive or inﬂammatory medial synovium had a more severe medial
chondropathy. The worsening in medial chondropathy after 1 year was statistically more severe in the group of patients with an inﬂammatory
perimeniscal synovial membrane at baseline compared to patients with normal and reactive aspects, with no difference between these two
latter groups. The odds ratio for progression in VAS score after 1 year was 3.11 (95% CI [1.07, 5.69]) for patients with inﬂammatory synovium
at baseline compared to patients with normal synovium.
Conclusions: This study suggests that abnormalities of the medial perimeniscal synovium are a common feature of painful medial knee OA,
associated with more severe medial chondropathy. It also suggests that an inﬂammatory aspect of the medial perimeniscal synovium could be
considered as a predictive factor of subsequent increased degradation of medial chondropathy.
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Osteoarthritis (OA) contributes greatly to overall disability in
the community1, with knee OA the greatest contributor. The
pain and gradual loss of joint function characteristic of OA
are associated with progressive loss of articular cartilage,
formation of osteophytes and joint remodeling. However,
OA is no longer considered a ‘‘degenerative’’ or ‘‘wear and
tear’’ disease but is now recognized to involve dynamic
biological and biochemical processes. The role of cytokines
in the progression of OA has received particular attention
because of the degree of the interaction between articular
cartilage and synovium in this pathology2. Chondrocytes
and synovial cells are targeted by cytokines such as
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Received 26 May 2004; revision accepted 4 January 2005.36interleukin-1 (IL-1) and tumor necrosis factor alpha (TNFa)
to produce matrix proteases and to suppress the synthesis
of collagen and proteoglycan3e6. Chronic inﬂammatory
changes with production of proinﬂammatory cytokines are
a feature of early7 and advanced7,8 knee OA. The low grade
synovitis may contribute to the progression of chondropathy
by accelerating the catabolism of articular cartilage.
Cartilage breakdown and synovial abnormalities can be
assessed by magnetic resonance imaging (MRI)9,10.
However, arthroscopy still remains the gold standard for
the assessment of these two intra-articular structures
because it provides a direct and magniﬁed evaluation of
them. Thus, alongside the use of arthroscopy as a di-
agnostic or therapeutic procedure in knee disorders,
a further function of knee arthroscopy, performed under
local anesthesia on an outpatient basis, has been pro-
posed: the monitoring and follow-up of knee chondropathy
and synovitis conducted for research purposes on patients
suffering from knee OA11e13. The development of this
arthroscopic outcome measurement of chondropathy and1
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systems for scoring the severity of chondral and synovial
lesions14e20.
In a previous arthroscopic longitudinal study of 46
patients suffering from patellofemoral chondropathy, we
found after 6 months a statistically signiﬁcant correlation
between the progression of patellofemoral chondropathy
and the presence and amount of synovitis at baseline12.
However, the small sample size of the study and the
characteristics of the recruited patients, i.e., post-traumatic
patellofemoral chondropathy, deny any deﬁnite conclusions
for patients suffering from primary knee OA.
In 2003, we published a large multicenter, randomized,
double-blind study aimed at comparing arthroscopically the
potential structure-modifying effect of tenidap sodium vs
piroxicam in medial knee OA21. This 1-year study failed to
demonstrate any difference between the treatment arms
with regard to the structural progression of medial knee OA
as measured by radiography and arthroscopy. Arthroscopy
did, however, appear more sensitive in detecting disease
progression than the weight-bearing radiographs in ex-
tended position. Since the arthroscopic aspects of synovial
membrane were also collected by the central reader, it gave
us the opportunity to analyze interrelation between synovitis
and cartilage damage.
The present arthroscopic study was conducted in this
large population of patients suffering from medial knee OA.
It aimed to evaluate the prevalence of synovitis and
correlation between structural severity of cartilaginous
damage and synovitis, and to analyze whether synovitis
could be considered as a predictive factor of structural
progression of knee OA.
Materials and methods
This study is derived from a large randomized study
comparing tenidap sodium and piroxicam21, in which
inclusion/exclusion criteria and study design were the
following.
PATIENTS
Inclusion criteria: patients with clinical involvement of the
medial tibiofemoral compartment of the knee (pain localized
at the medial part of the knee) and satisfying the American
College of Rheumatology criteria for knee OA22: pain in the
signal knee and either A or all the items under B
(AZ tibiofemoral osteophytes present on knee X-ray,
BZ (i) morning stiffness if present lasts less than 30 min,
(ii) crepitus present on active motion, (iii) synovial ﬂuid
collected in the last year with at least two of the following
features: clear, viscous, white blood cell count !2000/ml).
Other criteria for eligibility were: (1) age: 45e75 years, (2)
body mass index (BMI): 25e50, (3) active disease deﬁned
by pain of any duration in the signal knee on at least 30
days in the last 2 months and which might beneﬁt from joint
lavage, (4) ambulatory patient, (5) radiological joint space of
2 mm or greater at the narrowest point of the medial
compartment of the signal joint on weight-bearing radio-
graphs with knee fully extended, (6) no lesion requiring
surgery (e.g., of meniscus, cartilage or ligament) at
screening arthroscopy, or likely to require surgery during
study period, (7) presence of chondropathy of the medial
compartment at entry, approved by central reader of video
made during screening arthroscopy; for approval, at least
10% of one articular surface of the medial compartment(femoral condyle or tibial plateau) had to be affected by
superﬁcial ﬁbrillation or worse; if 90% or greater of both
surfaces showed absence of cartilage, the patient was not
eligible.
Exclusion criteria were the following: (1) knee OA
secondary to other bone or joint disease, (2) initial diagnosis
of knee OA made by a physician more than 10 years
previously, (3) any of the following procedures prior to the
screening arthroscopy: injury to joint and arthroscopy within
2 months prior to entry, intra-articular injection within 3
months, intra-articular surgery including meniscal trimming
within 2 years, osteotomy within 3 years, (4) any chronic
inﬂammatory joint disease, including rheumatoid arthritis,
ankylosing spondylitis and crystal arthropathies, (5) treat-
ment with corticosteroids (oral, intravenous, intramuscular)
in last 3 months, previous tenidap treatment in last 4 months
and piroxicam within 1 month.
STUDY DESIGN
This longitudinal, prospective, multicenter study of 1-year
duration involved 45 centers in Europe, America and
Australia. The study was conducted according to the
Declaration of Helsinki (Revised Hong Kong 1989) and
received ethics approval at each center. Each patient gave
written, informed consent prior to recruitment. Arthroscopy
videotapes were sent to central reader (Xavier Ayral,
Cochin, Paris) for quality control and assessment of the
arthroscopic inclusion criteria. After satisfaction of all entry
criteria, patients were randomized equally to one of the
three study groups (tenidap 40 mg, tenidap 120 mg,
piroxicam 20 mg). Rescue treatment by paracetamol was
dispensed as required. This study failed to demonstrate
a structural modiﬁcation21. The development of such
compound (tenidap) is currently no more developed.
DATA COLLECTION IN THE PRESENT STUDY
At baseline
Demographic data. Demographic data were noted, includ-
ing age, sex, BMI, and disease duration.
Symptomatic severity of OA. Symptomatic severity of OA
was assessed, before arthroscopy, using the following
variables: Western Ontario and McMaster Universities
(WOMAC) global and its three subscales: pain, stiffness,
physical function measured using a ﬁve-point Likert scale
(none, mild, moderate, severe, very severe)23, patient and
physician assessment of global status measured using
a ﬁve-point Likert scale.
Radiological variables. Radiological evaluation consisted
of bilateral anteroposterior weight-bearing knee radiographs
with the knees fully extended. The severity of OA of the
medial tibiofemoral compartment was evaluated by a single
investigator using Kellgren and Lawrence grading24 and by
measuring the joint space width in millimeters at the
narrowest point of the medial compartment, using a 10!
lupe scaled to 0.1 mm.
At baseline and after 12 months
Arthroscopy. Arthroscopy of the knee was performed under
local anesthesia, without tourniquet hemostasis, with
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(2.7 mm), having both a 30( fore oblique lens, using the
lateral infrapatellar approach. Usually, the same size of
arthroscope was used at entry and after 12 months.
Arthroscopic exploration was combined with joint lavage,
the volume of which consisted of 1 l of normal saline. Only
the exploration of the medial compartment was recorded on
a VHS videotape (Sony, Tokyo, Japan). Videorecording of
articular cartilage surface of the femoral condyle and tibial
plateau was standardized as previously reported20. Almost
all centers had only one arthroscopist who performed all
procedures. Prior to screening their ﬁrst patient, a center
had to provide a videotape to the central reader demon-
strating successful use of the required technique. During
the study, all screening videotapes were sent to the central
reader for conﬁrmation of eligibility and feedback to the
arthroscopist.
Evaluation of medial tibiofemoral chondropathy. Two
scoring methods were used: the overall assessment of the
investigator14 and the Socie´te´ Franc¸aise d’Arthroscopie
(SFA) scoring system15,16.
The overall assessment of chondropathy uses a 100 mm
VAS in which 0 indicates the absence of chondropathy and
100 the most severe chondropathy. One VAS is used for
each articular surface, i.e., medial femoral condyle and
medial tibial plateau. A VAS score is calculated for the
medial tibiofemoral compartment by averaging the VAS
scores from the medial condyle and plateau.
In the SFA scoring system, the ﬁrst step consists of
reporting on an articular diagram of the knee, the observed
chondropathy with three main baseline variables: (1)
location: medial femur and medial tibia, (2) depth based
on the classiﬁcation of chondropathy proposed by Beguin
and Locker25, in which grade 0 indicates normal cartilage,
grade I swelling and/or softening, grade II superﬁcial
ﬁbrillations, grade III deep ﬁbrillations down to bone, and
grade IV exposure of subchondral bone, (3) extent from 0%
to 100% of the involved articular surface. Extent of lesions
is estimated by the investigator as a percentage of the
whole articular surface and is reported on a special form.
The composite index of severity of chondropathy of the
medial compartment takes into account location, depth, and
extent of cartilage lesions of the compartment. It is called
the SFA score, which is a continuous variable, between
0 and 100, obtained as follows: SFA scoreZ extent (%) of
grade I lesions! 0.14C extent (%) of grade II lesions!
0.34C extent (%) of grade III lesions! 0.65C extent (%)
of grade IV lesions! 1.00. For the medial compartment,
the extent (%) of grades 0eIV corresponds to the mean
value of the extent of the grade of the two articular surfaces
of the compartment, i.e., medial femoral condyle and tibial
plateau.
Evaluation of medial perimeniscal synovium. Themedial
perimeniscal synovium is the thin fringe of synovium
covering the attachment of joint capsule along the periphery
of medial meniscus. Three aspects of increasing intensity of
synovial macroscopic abnormalities have been deﬁned by
Watanabe et al.26. Normal synovium involves few trans-
lucent and slender villi formations with a ﬁne vascular
network clearly seen. The reactive aspect shows a pro-
liferation of opaque villi formations of enhanced number.
These villi show a normal morphology or appear somewhat
thicker and squat (aspect of ‘‘cut grass’’). The vascular
network cannot be seen due to loss of translucence. In the
inﬂammatory aspect, there is hypervascularization of
the synovial membrane and/or proliferation of hypertrophic
and hyperemic villi formations. This aspect is similar toinﬂammatory joint diseases but may occur in knee OA. The
perimeniscal area is a small area and the aspect of the
corresponding synovial membrane is homogenous, either
normal, reactive or inﬂammatory, without a patchy distribu-
tion.
STUDY SCHEDULE
Arthroscopic evaluations were performed at entry and
after 1 year, and videorecorded on two separate video-
tapes. The paired arthroscopy videotapes of each patient
were analyzed by one investigator (XA) using a blind
procedure in which the investigator was unaware of the
patient’s identity and unaware of the chronology of the
arthroscopy videotapes.
STATISTICAL ANALYSIS
In the cross-sectional study, statistical analyses were
performed to assess the prevalence of the different synovial
aspects in painful knee OA and to evaluate relations
between the three synovial aspects and the severity of
medial chondropathy. The comparisons for SFA score and
for VAS score at baseline were based on one-way ANOVA.
In the longitudinal study, statistical analyses were
performed to evaluate relations between the three synovial
aspects at baseline and the arthroscopic progression of
medial chondropathy after 1 year. The comparisons for
change in SFA score and for change in VAS score after 1
year were based on one-way ANOVA. Based on the
reported results of intra-observer reliability of the arthro-
scopic quantiﬁcation of chondral lesions by the central
reader11, a change of over 4.5 for the SFA score and over
8.0 mm for the VAS score can be considered as worsening
related to disease progression (called ‘‘progressors’’) and
not related to the variability of the measurement. The




Four hundred and twenty-two patients were enrolled and
completed the 1-year study. Their baseline characteristics
are summarized in Table I.
CROSS-SECTIONAL STUDY
Prevalence of synovitis
Synovial abnormalities (called ‘‘synovitis’’) were present
in 212 patients over 422 (50%), with 123 patients (29%) with
a reactive aspect and 89 (21%) with an inﬂammatory aspect
of the medial perimeniscal synovium (Table I).
Relation between synovitis and medial
chondropathy
Patients with a reactive or inﬂammatory medial perime-
niscal synovium had a more severe medial chondropathy
(assessed by the SFA and the VAS scores) than patients
with a normal synovium, with a tendency for a more severe
chondropathy in the inﬂammatory group compared to the
reactive group (Table II).
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Change of medial chondropathy after 1 year
There was a statistically signiﬁcant worsening in medial
chondropathy after 1 year by using the SFA and the VAS
scores (Table III).
Relationship between synovial aspects
at baseline and progression of medial
chondropathy after 1 year
The worsening in medial chondropathy after 1 year was
statistically more severe in the group of patients with an
inﬂammatory perimeniscal synovial membrane at baseline
compared to patients with normal and reactive aspects, with
no difference between these two latter groups. This
difference was found by using continuous variables (SFA
score and VAS score) and categorical variables (% of
progressors) to quantify chondropathy change (Table IV).
The odds ratio for progression in SFA score was 2.58 (95%
CI of [1.37, 4.85]) for inﬂammatory synovium compared to
normal and was 1.11 (95% CI of [0.57, 2.17]) for reactive
synovium compared to normal. The odds ratio for pro-
gression in VAS score was 3.11 (95% CI of [1.07, 5.69]) for
inﬂammatory synovium compared to normal and was 1.01
Table I
Baseline characteristics (nZ 422)
Demographic data mGSD
Age (years) 61.2G 7.7
Sex (F%/M%) 59/41
BMI 30.5G 4.7
Disease duration (years) 3.7G 2.9
Clinical activity
WOMAC global (0e100) 40.4G 17.1
WOMAC pain (0e100) 38.4G 18.6
WOMAC stiffness (0e100) 40.3G 22.2
WOMAC function (0e100) 41.9G 18.1
Patient assessment (0e100) 52.1G 18.9
Physician assessment (0e100) 51.6G 17.4
Radiological severity
Joint space width (mm) 3.9G 1.4








SFA score (0e100) 34.8G 19.6
Overall assessment (100 mm VAS) 38.4G 18.0
Medial perimeniscal synovium
Synovium (normal/reactive/inﬂammatory) 210/123/89
Synovitis (no/yes) 210/212(95% CI of [0.52, 1.97]) for reactive synovium compared to
normal.
Discussion
This large prospective study conﬁrms that arthroscopic
abnormalities of the medial perimeniscal synovial mem-
brane, i.e., reactive and inﬂammatory aspects, are frequent
in painful medial knee OA and associated with more severe
chondropathy than normal synovium. This study suggests
also that an inﬂammatory aspect of the medial perimeniscal
synovium could be predictive of subsequent increased
degradation of medial chondropathy.
The present study derived from a randomized study
comparing arthroscopically the structural effect of tenidap
sodium, 40 or 120 mg daily, and piroxicam 20 mg daily on
articular cartilage, with 494 completers after 1 year21. This
previous study was not initially designed for synovium
examination and only 422 patients had suitable video-
recording of medial perimeniscal synovium on paired
videotapes at entry and after 1 year. One could argue that
difference in non-steroidal anti-inﬂammatory drugs
(NSAIDs) and dosage could interfere with the analysis of
cartilage progression. However, in the ‘‘tenidap study’’, the
intragroup arthroscopic deterioration of chondropathy after
1 year was low, but statistically signiﬁcant in the three study
groups, but there was no statistically signiﬁcant difference
between treatment groups for the change in SFA and VAS
scores after 1 year. For this reason, we considered that we
were allowed to pool the patients together for synovial
examination.
Regardless of clinical diagnosis (OA or various types of
arthritis), Linblad and Hedfors27 found a profound articular
variation in the macroscopic signs of inﬂammatory activity
as seen at arthroscopy, with the highest inﬂammatory
changes of the synovial membrane always conﬁned to the
area surrounding the cartilage lesions. For these authors,
the area of the synovial membrane near the cartilage seems
to be crucial in the initiation as well as in the modulation of
synovitis, irrespective of diagnosis. Thus, focusing the
evaluation of synovial membrane on the medial perimenis-
cal synovium in medial tibiofemoral knee OA was consid-
ered adequate. Since videorecording of arthroscopy
exploration was limited to the medial tibiofemoral compart-
ment, we were unable to analyze relation between the
medial perimeniscal synovium aspect, on one hand, and
synovial aspects and cartilage lesions or progression of
cartilage lesions in patellofemoral and lateral tibiofemoral
compartments, on the other hand. However, since the
inﬂammatory areas of synovium are usually adjacent to
damaged articular cartilage in OA (focal synovitis), it seems
unlikely that the evolution of patellofemoral and lateral
tibiofemoral compartments inﬂuences the medial perime-
niscal synovium. Moreover, patients included in this study
were suffering from medial knee OA and not from lateral or
patellofemoral knee OA.Table II
Cross-sectional study: comparison of the severity of medial chondropathy with regard to synovial aspects (nZ 422)
Chondropathy (day 0) Medial perimeniscal synovium (day 0) P * P ** P ***
Normal (nZ 210) Reactive (nZ 123) Inﬂammatory (nZ 89)
SFA score (0e100) 29.7G 18.6 38.0G 20.2 42.1G 17.8 !0.0001 !0.0001 0.1665
VAS score (100 mm) 34.1G 16.8 41.0G 19.2 44.8G 16.7 0.0003 !0.0001 0.1341
P-value: ANOVA. *P-value of reactive synovium vs normal synovium. **P-value of inﬂammatory synovium vs normal synovium.
***P-value of inﬂammatory synovium vs reactive synovium.
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1 year (mG SD)
P *
SFA score (0e100) 34.8G 19.6 36.5G 20.0 1.7G 4.9 !0.0001
VAS score (100 mm) 38.4G 18.0 41.2G 19.3 2.8G 6.4 !0.0001
*Student’s paired t test.It should be noted that we did not perform synovial
biopsies in this study to compare the microscopic in-
ﬂammatory features with the macroscopic synovial abnor-
malities. However, previous studies comparing arthroscopic
and histological examinations have found a close correla-
tion between macroscopic and microscopic ﬁndings27e29.
Linblad and Hedfors27 found in 10 OA patients that the
macroscopic variation of inﬂammatory intensity of the
synovial membrane was signiﬁcantly correlated to a micro-
scopic variation of the immunohistopathologic patterns.
Biopsies sampled from macroscopically intensely inﬂamed
areas, showing formation of highly vascularized hyperemic
villi (corresponding to our ‘‘inﬂammatory aspect’’) comprised
in all cases foci of T lymphocytes displaying a picture
previously thought characteristic of rheumatoid arthritis. In
contrast, in tissues sampled within the same joint from
areas with macroscopic signs of slight or no inﬂammation,
the microscopic examination revealed a non-proliferated
lining layer and sublining but a few inﬁltrating lymphocytes,
thus showing a histopathologic picture usually perceived as
either normal or characteristic of OA.
One limitation of the study is that intra- and inter-observer
reliability of the qualitative method for synovium evaluation
has not been investigated, neither in the present study, nor
in the previous study evaluating patellofemoral chondrop-
athy12, even though the central reader of arthroscopy
videotapes was the same in both studies (XA).
In our previous study12, we analyzed synovial abnormal-
ities in 59 painful patellofemoral chondropathy, induced by
direct trauma (54%) or by overuse (46%) in young patients
(36 years old) with mild patellofemoral chondropathy (SFA
score: 7, VAS score: 11 mm). In this population of patients,
which could be considered as early OA, reactive and
inﬂammatory synovial aspects were pooled together and
were present in 16 (27%) of the patients. In the present
study, synovial abnormalities were more frequent since they
were present in 50% of the patients, with an inﬂammatory
aspect in 21%. The disease duration was the same in both
studies (4 years) and cannot explain this difference
between prevalence of synovial abnormalities. The majordifference between the two populations is a more severe
chondropathy in the medial tibiofemoral group (SFA score:
35, VAS score: 38 mm). Different authors have reported
a signiﬁcant correlation between synovitis and severity of
chondropathy in knee OA7,8,27. Most authors consider
synovitis in OA as a secondary phenomenon related to
cartilage and bone alteration and induced by the release of
degradative compounds from the extracellular matrix of
hyaline cartilage and the presence of microcrystals in the
synovial ﬂuid and the synovium3,30,31. Schumacher et al.8
examined 150 knees in consecutive autopsies that included
30 patients with severe OA and 78 with no or minimal OA.
Only 12 of 78 synovial membranes from patients with
minimal or no OA had either lining cell proliferation or
lymphocyte inﬁltration, compared to 36 of 78 knees from
patients with moderate or severe OA. Smith et al.7
conﬁrmed arthroscopically that the most marked changes
in synovial tissues of the knee joint are seen with advanced
grades of OA, but they also pointed out that chronic
inﬂammatory changes are present in synovial membrane
from patients with early OA. The greater the articular
cartilage breakdown, the greater the synovial reaction. This
picture is illustrated by the result of our cross-sectional
study showing a parallel increase of chondropathy and
synovitis. However, the difference in cartilage damage
between synovium groups was small suggesting that other
factors than the tibiofemoral chondropathy could play a role
in synovium aspects.
The most interesting ﬁnding of the present study is that
the presence of inﬂammatory synovium at baseline could
be predictive of structural progression of cartilage lesions.
This data was suggested by our previous longitudinal study
with an arthroscopic 6-months follow-up of 46 patellofe-
moral chondropathies, but with no distinction between the
inﬂammatory and the reactive aspect of synovium at
baseline12. In 422 medial knee OA, we found the presence
of inﬂammatory perimeniscal synovium to be predictive of
a more important worsening of medial chondropathy after 1
year compared to patients with normal and reactive
synovium, with no difference between these two latterTable IV
Longitudinal study: relationship between the aspect of medial perimeniscal membrane at baseline and the evolution of medial chondropathy
after 1 year (nZ 422)
Medial chondropathy
(change after 1 year)
Medial perimeniscal synovium at baseline P * P ** P ***
Normal (nZ 210) Reactive (nZ 123) Inﬂammatory (nZ 89)
SFA score (0e100) 1.4G 3.7 1.3G 5.6 3.1G 6.2 0.7323 0.0535 0.0427
VAS score (100 mm) 2.2G 5.1 2.1G 6.6 5.0G 8.1 0.8844 0.0055 0.0084
%SFA score progressorsy 11.9% 13.0% 25.8% 0.7675 0.0033 0.0192
%VAS score progressorsz 12.9% 13.0% 31.5% 0.9684 0.0002 0.0014
P-value: ANOVA, for change in SFA score and VAS score; exact P-values based odds ratios derived from logistic regression, for comparing
% progressors. *P-value of reactive synovium vs normal synovium. **P-value of inﬂammatory synovium vs normal synovium. ***P-value
of inﬂammatory synovium vs reactive synovium.
y% of patients with (ﬁnal SFA score baseline SFA score)O 4.5.
z% of patients with (ﬁnal VAS score baseline VAS score)O 8.0 mm.
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baseline in the inﬂammatory group compared to normal
group could be a confounding factor for cartilage damage
progression; conversely, the absence of statistically signif-
icant difference of severity of chondropathy at baseline
between the reactive and inﬂammatory groups suggests that
the inﬂammatory aspect of the synovium could be a potential
predictive factor of progression of chondropathy. This
arthroscopic inﬂammatory aspect corresponds to the most
inﬂammatory immunohistopathologic pattern for Linblad and
Hedfors27. The role of cytokines in the progression of OA
has received particular attention because of the degree of
the interaction between articular cartilage and synovium in
this pathology. Chondrocytes and synovial cells are targeted
by cytokines such as IL-1 and TNFa to produce matrix
proteases and to suppress the synthesis of collagen and
proteoglycan3. In the triangular relationship among severity
of chondropathy, synovitis and progression of chondrop-
athy, synovitis may contribute to the progression of
chondropathy by a direct deleterious effect on cartilage.
However, it could also be suggested that synovitis is just
a marker for advanced and/or active cartilage breakdown,
without a catabolic effect on cartilage. In practice, detection
of inﬂammatory synovium at arthroscopy near area of
chondropathy suggests active cartilage breakdown requir-
ing an appropriate treatment and a thorough follow-up.
It should be noted that the results of this longitudinal
study were obtained in patients treated continuously with an
NSAID (tenidap 40 or 120 mg, or piroxicam 20 mg) during
the 1-year duration of the study. In the absence of a long-
term anti-inﬂammatory treatment, would have been the
progression of chondropathy more important in the in-
ﬂammatory group? Could we imagine that a long-term
treatment with an NSAID might slow structural progression
of painful OA with recognized inﬂammatory synovitis? In the
absence of a placebo group in the multicenter study
comparing tenidap sodium vs piroxicam21, we are unable
to conclude. Further studies are required.
If we consider that inﬂammatory synovium is a potential
predictive factor of structural progression in OA, its
recognition with non-invasive methods would be of interest
in order to initiate appropriate therapies in clinical practice
and to select patients at higher risk of cartilage degradation
in clinical trials evaluating potential structure-modifying
drugs. Different authors reported a correlation between
knee effusion and the presence of synovitis at arthro-
scopy12,28, even though no correlation was found between
synovitis and the level of pain or functional impairment12.
However, it should be pointed out that these arthroscopic
studies evaluate exclusively painful patients, which could
induce a systematic bias in the analysis of correlation
between pain and synovial reaction. At this time, knee
effusion seems to be a simple clinical signal of a ﬂare of the
disease, i.e., a clinical signal of a probable intra-articular
inﬂammatory process with a potential risk of accelerated
cartilage degradation32. In clinical research, the use of
ultrasonography and MRI will permit to detect and to follow
non-invasively OA patients with a synovial reaction and will
permit to reanalyze correlation between synovitis and
clinical parameters in painful and painless OA patients.
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